Inhibition of myeloid differentiation factor 88(MyD88) by ST2825 provides neuroprotection after experimental traumatic brain injury in mice
详细信息 查看全文
- 作者：Hua-Sheng Zhanga ; 1 ; 2 ; 3 ; 4 ; 5 ; 6 ; Hua Lib ; 1 ; 3 ; 6 ; Ding-Ding Zhanga ; 3 ; Hui-Ying Yana ; 4 ; Zi-Huan Zhangc ; 4 ; Chen-Hui Zhoua ; 4 ; Zhen-Nan Yed ; 5 ; Qiang Chend ; 5 ; Tian-Wei Jianga ; 6 ; Jing-Peng Liud ; Chun-Hua Hanga ; d ; 2 ; 7 ; hang_neurosurgery@163.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：TBI ; traumatic brain injury ; MyD88 ; myeloid differentiation factor 88 ; TAK1 ; transforming growth factor-b-activated kinase 1 ; NF-κB ; nuclear factor kappa B ; TNF-α ; tumor necrosis factor-α ; IL-1β ; interlukin-1β ; ELISA ; enzyme-linked immunosorbent assay ; BBB ; blood brain barrier ; TUNEL ; terminal deoxynucleotidyl transferase-mediated uridine 5&prime ; -triphosphate&ndash ; biotin nick end-labeling ; IRAK ; IL-1 ; R-associated kinase
- 刊名：Brain Research
- 出版年：2016
- 出版时间：15 July 2016
- 年：2016
- 卷：1643
- 期：Complete
- 页码：130-139
- 全文大小：2209 K
文摘
- •
This is the first study to reveal the effect of MyD88 inhibitor ST2825 after TBI.
- •
ST2825 reduced neural apoptosis and improved neurological function after TBI.
- •
MyD88-mediated signaling may be a promising target for intervention after TBI.